Synthetic Biologics (SYN) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts SYN Hot Sheet
Join SI Premium – FREE
Synthetic Biologics (NYSE: SYN) reported Q1 EPS of ($0.02), $0.05 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on Synthetic Biologics (SYN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Constellation Brands (STZ) Beats Q2 EPS by 13c, Revenue Beats, Offers Guidance
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c; raises guidance
- Saratoga Investment (SAR) Misses Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
